Patent Armory v. Humana: Voluntary Dismissal in Call Routing Patent Dispute

Case Overview

In a case that closed faster than most patent disputes reach their first scheduling conference, Patent Armory, Inc. voluntarily dismissed its patent infringement action against Humana, Inc. with prejudice just 126 days after filing. Case No. 7:25-cv-00151, resolved in the Western District of Texas on August 6, 2025, centered on intelligent communication routing and telephony control patents—technology directly relevant to healthcare call center and customer routing operations.

The rapid resolution through voluntary dismissal under Federal Rule of Civil Procedure 41(a)(1)(A)(i), before Humana filed any responsive pleading, raises significant strategic questions about patent assertion entity (PAE) litigation dynamics, licensing negotiation timelines, and the continued appeal of the Western District of Texas as a patent litigation venue. For patent attorneys, IP professionals, and R&D teams operating in telecommunications and healthcare technology, this case offers pointed lessons about enforcement strategy, pre-answer resolution, and freedom-to-operate risk management.

The Parties

Patents at Issue

Five U.S. patents were asserted, all relating to intelligent communication routing and telephony systems:

• • US9456086B1 — Intelligent communication routing (App. No. 12/719827)
• • US10491748B1 — Communication routing systems (App. No. 15/797070)
• • US7269253B1 — Telephony control with intelligent call routing (App. No. 11/387305)
• • US7023979B1 — Method and system for matching entities in an auction (App. No. 10/385389)
• • US10237420B1 — Communication routing methods (App. No. 15/856729)

The Verdict & Legal Analysis

Outcome

On August 5, 2025, Patent Armory filed a Notice of Voluntary Dismissal With Prejudice pursuant to Fed. R. Civ. P. 41(a)(1)(A)(i). The Western District of Texas issued its closing order on August 6, 2025. The dismissal was with prejudice, meaning Patent Armory permanently relinquished its right to re-assert these specific claims against Humana. Each party bears its own costs, expenses, and attorney fees per the court’s order. No damages were awarded. No injunctive relief was granted.

Verdict Cause & Legal Significance

The legal mechanism here is straightforward but strategically significant. Rule 41(a)(1)(A)(i) permits a plaintiff to unilaterally terminate an action—without court involvement—so long as the defendant has not yet served an answer or motion for summary judgment. As the Fifth Circuit confirmed in In re Amerijet Int’l, Inc., 785 F.3d 967, 973 (5th Cir. 2015), such a notice is “self-effectuating and terminates the case in and of itself.”

The with prejudice designation is the pivotal distinction. A without-prejudice dismissal preserves the plaintiff’s option to refile. A with-prejudice dismissal operates as a final judgment on the merits under res judicata principles—Patent Armory cannot reassert these patents against Humana on the same claims. This suggests either: (1) a confidential settlement or licensing agreement was reached, making continued litigation unnecessary; or (2) Patent Armory strategically withdrew after evaluating Humana’s anticipated defenses, cost trajectory, or IPR exposure.

For patent assertion entities operating in the communications technology space, this case illustrates how rapid, pre-answer dismissals—particularly with prejudice—frequently signal background licensing activity rather than litigation failure. The absence of any defendant-side filings makes it difficult to assess substantive invalidity or non-infringement arguments that may have influenced the plaintiff’s calculus.